RGN-259 (thymosin β4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model
Abstract This study evaluated the clinical activity of RGN-259 (thymosin β4) in comparison with cyclosporine A (CsA), diquafosol (DQS), and lifitegrast (LFA) in a murine model of dry eye. The model was NOD.B10-H2 b mice in a 30–40% humidified environment together with daily scopolamine hydrobromide...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-018-28861-5 |